The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Zyryanov S.K.
Patrice Lumumba Peoples’ Friendship University of Russia;
City Clinical Hospital No. 24
Modern approaches to rational combination pharmacotherapy of allergic rhinitis
Journal: Russian Bulletin of Otorhinolaryngology. 2024;89(4): 68‑77
Views: 656
Downloaded: 3
To cite this article:
Zyryanov SK, Vozzhaev AV. Modern approaches to rational combination pharmacotherapy of allergic rhinitis. Russian Bulletin of Otorhinolaryngology.
2024;89(4):68‑77. (In Russ.)
https://doi.org/10.17116/otorino20248904168
Allergic rhinitis (AR) can significantly reduce the quality of life of patients leading to increased fatigue, mood changes, cognitive impairment, and depression. In clinical practice, insufficient effectiveness of initial AR monotherapy is often noted, and a significant proportion of patients referring for medical care have moderate-severe AR. In this regard, the issues of optimization of combined pharmacological treatment of AR are becoming more and more urgent. This paper provides analysis of the opportunities of combined pharmacotherapy within the framework of current management strategy of AR. Based on the results of some studies and known pharmacological properties of medications it is being discussed the advantages of combined use of intranasal corticosteroids and leukotriene receptor antagonists, in particular mometasone furoate and montelukast, in the therapy of AR, including such comorbidities as bronchial asthma, chronic polyposis rhinosinusitis and pharyngeal tonsil hyperplasia. Some aspects of combination therapy with montelukast and second-generation systemic antihistamines as an alternative approach in case of inability to take intranasal corticosteroids, including the reasonability of using a fixed combination of montelukast and levocetirizine, are analyzed from the perspective of rational pharmacotherapy. The problem of interchangeability of brand-name and generic drugs for the treatment of AR is discussed, considering the almost complete absence of studies of their therapeutic equivalence.
Keywords:
Authors:
Zyryanov S.K.
Patrice Lumumba Peoples’ Friendship University of Russia;
City Clinical Hospital No. 24
Received:
01.06.2024
Accepted:
03.06.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.